Discontinuation of biologic DMARDs in non-systemic JIA patients: a scoping review of relapse rates and associated factors

BACKGROUND: Biologic disease-modifying antirheumatic drugs (bDMARDs) have changed the treatment of juvenile idiopathic arthritis (JIA) patients notably, as bDMARDs enable substantially more patients to achieve remission. When sustained remission is achieved, tapering or even discontinuation of the b...

Descripción completa

Detalles Bibliográficos
Autores principales: Gieling, Job, van den Bemt, Bart, Hoppenreijs, Esther, Schatorjé, Ellen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721079/
https://www.ncbi.nlm.nih.gov/pubmed/36471348
http://dx.doi.org/10.1186/s12969-022-00769-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721079/
https://www.ncbi.nlm.nih.gov/pubmed/36471348
http://dx.doi.org/10.1186/s12969-022-00769-5

Ejemplares similares